Aurobindo Pharma Ltd.
AUROPHARMAHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
31 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 31 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20190222 | 2018-12-31 | yes | |
| TRANSCRIPT | 20190614 | 2019-03-31 | yes | |
| TRANSCRIPT | 20190819 | 2019-06-30 | yes | |
| TRANSCRIPT | 20191128 | 2019-09-30 | yes | |
| TRANSCRIPT | 20200224 | 2019-12-31 | yes | |
| TRANSCRIPT | 20200618 | 2020-03-31 | yes | |
| TRANSCRIPT | 20200825 | 2020-06-30 | yes | |
| TRANSCRIPT | 20201127 | 2020-09-30 | yes | |
| TRANSCRIPT | 20210225 | 2020-12-31 | yes | |
| TRANSCRIPT | 20210611 | 2021-03-31 | yes | |
| TRANSCRIPT | 20210825 | 2021-06-30 | yes | |
| TRANSCRIPT | 20211119 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220217 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220606 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220819 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221118 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230217 | 2022-12-31 | yes | |
| TRANSCRIPT | 20240216 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230601 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230818 | 2023-06-30 | yes | |
| TRANSCRIPT | 20240816 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231115 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240531 | 2024-03-31 | yes | |
| TRANSCRIPT | 20241118 | 2024-09-30 | yes | |
| TRANSCRIPT | 20260216 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250213 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250602 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250808 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251111 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260527 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260813 | 2026-06-30 | yes |
AUROPHARMA
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,716.00 |
| 52-week range | 1070.8 – 1734.0 |
| Return 1M | 6.07% |
| Return 3M | 10.34% |
| Return 1Y | 57.3% |
| Return 3Y | 96.42% |
| Return 5Y | 137.82% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 9,150.00 |
| Other income | 264.00 |
| Total income | 9,415.00 |
| Cost of materials consumed | 2,894.00 |
| Purchases of stock-in-trade | 932.00 |
| Changes in inventories | -199.00 |
| Employee benefit expense | 1,480.00 |
| Finance costs | 102.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.52 | 0.00 |
| institutions foreign | 0.16 | 0.01 |
| institutions domestic | 0.25 | -0.01 |
| mutual funds | 0.17 | -0.01 |
| public | 0.48 | -0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 31 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 5,739.00 | 6,407.00 | 6,473.00 | 6,851.00 | 7,219.00 | 7,352.00 | 7,580.00 | 7,567.00 | 7,796.00 | 7,979.00 | 8,382.00 | 7,868.00 | 8,286.00 | 8,646.00 | 8,853.00 | 9,150.00 |
| Other income | 57.00 | 93.00 | 135.00 | 116.00 | 187.00 | 163.00 | 136.00 | 221.00 | 136.00 | 157.00 | 135.00 | 105.00 | 121.00 | 188.00 | 117.00 | 264.00 |
| Total income | 5,797.00 | 6,500.00 | 6,608.00 | 6,967.00 | 7,406.00 | 7,514.00 | 7,716.00 | 7,788.00 | 7,932.00 | 8,136.00 | 8,517.00 | 7,973.00 | 8,406.00 | 8,834.00 | 8,970.00 | 9,415.00 |
| Cost of materials consumed | 2,349.00 | 2,621.00 | 2,671.00 | 2,757.00 | 2,709.00 | 2,676.00 | 2,635.00 | 2,467.00 | 2,742.00 | 2,729.00 | 2,800.00 | 2,535.00 | 2,510.00 | 2,755.00 | 2,505.00 | 2,894.00 |
| Purchases of stock-in-trade | 435.00 | 538.00 | 589.00 | 580.00 | 631.00 | 776.00 | 786.00 | 680.00 | 747.00 | 824.00 | 636.00 | 808.00 | 846.00 | 893.00 | 931.00 | 932.00 |
| Changes in inventories | -215.00 | -252.00 | -328.00 | -182.00 | -103.00 | -301.00 | -360.00 | -74.00 | -279.00 | -237.00 | -8.00 | -104.00 | -17.00 | -166.00 | -8.00 | -199.00 |
| Employee benefit expense | 868.00 | 922.00 | 852.00 | 952.00 | 955.00 | 990.00 | 1,026.00 | 1,072.00 | 1,109.00 | 1,132.00 | 1,163.00 | 1,229.00 | 1,277.00 | 1,310.00 | 1,374.00 | 1,480.00 |
| Finance costs | 25.00 | 45.00 | 56.00 | 57.00 | 68.00 | 76.00 | 89.00 | 111.00 | 113.00 | 118.00 | 115.00 | 98.00 | 95.00 | 93.00 | 98.00 | 102.00 |
| Depreciation and amortisation | 298.00 | 321.00 | 346.00 | 327.00 | 418.00 | 423.00 | 354.00 | 404.00 | 382.00 | 419.00 | 444.00 | 406.00 | 429.00 | 465.00 | 479.00 | 487.00 |
| Other expenses | 1,512.00 | 1,623.00 | 1,688.00 | 1,592.00 | 1,654.00 | 1,610.00 | 1,820.00 | 1,803.00 | 1,910.00 | 1,954.00 | 2,000.00 | 1,797.00 | 1,991.00 | 2,081.00 | 2,298.00 | 2,162.00 |
| Total expenses | 5,272.00 | 5,819.00 | 5,872.00 | 6,082.00 | 6,332.00 | 6,249.00 | 6,351.00 | 6,463.00 | 6,725.00 | 6,938.00 | 7,150.00 | 6,769.00 | 7,132.00 | 7,430.00 | 7,677.00 | 7,858.00 |
| Profit before exceptional items and tax | 525.00 | 681.00 | 736.00 | 885.00 | 1,075.00 | 1,265.00 | 1,365.00 | 1,325.00 | 1,207.00 | 1,198.00 | 1,367.00 | 1,205.00 | 1,274.00 | 1,403.00 | 1,293.00 | 1,557.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | -70.00 | 0.00 | 0.00 | -122.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -65.00 | 0.00 | -40.00 |
| Profit before tax | 525.00 | 681.00 | 736.00 | 815.00 | 1,075.00 | 1,265.00 | 1,243.00 | 1,325.00 | 1,207.00 | 1,198.00 | 1,367.00 | 1,205.00 | 1,274.00 | 1,338.00 | 1,293.00 | 1,517.00 |
| Current tax | 166.00 | 136.00 | 580.00 | 340.00 | 482.00 | 385.00 | 571.00 | 449.00 | 322.00 | 498.00 | 431.00 | 491.00 | 463.00 | 383.00 | 399.00 | 610.00 |
| Deferred tax | -53.00 | 53.00 | -356.00 | -98.00 | -158.00 | -62.00 | -248.00 | -44.00 | 68.00 | -144.00 | 2.00 | -108.00 | -35.00 | 45.00 | -29.00 | -127.00 |
| Tax expense | 113.00 | 189.00 | 224.00 | 242.00 | 324.00 | 322.00 | 323.00 | 406.00 | 391.00 | 354.00 | 432.00 | 383.00 | 428.00 | 429.00 | 370.00 | 483.00 |
| Profit for the period | 410.00 | 491.00 | 506.00 | 570.00 | 752.00 | 940.00 | 907.00 | 918.00 | 817.00 | 846.00 | 903.00 | 824.00 | 848.00 | 910.00 | 921.00 | 1,032.00 |
| Profit attributable to owners | 409.00 | 491.00 | 506.00 | 571.00 | 757.00 | 936.00 | 909.00 | 919.00 | 817.00 | 855.00 | 903.00 | 825.00 | 848.00 | 910.00 | 921.00 | 1,033.00 |
| Profit attributable to non-controlling interests | 1.00 | -0.00 | -0.00 | -1.00 | -5.00 | 4.00 | -1.00 | -1.00 | -0.00 | -0.00 | -1.00 | -1.00 | -0.00 | -0.00 | -0.00 | -1.00 |
| Other comprehensive income | 69.00 | 477.00 | 13.00 | -30.00 | 51.00 | 189.00 | -111.00 | -41.00 | 270.00 | -65.00 | 140.00 | 406.00 | 541.00 | 228.00 | 791.00 | -47.00 |
| Total comprehensive income | 479.00 | 968.00 | 519.00 | 539.00 | 803.00 | 1,129.00 | 797.00 | 877.00 | 1,087.00 | 780.00 | 1,042.00 | 1,230.00 | 1,389.00 | 1,138.00 | 1,711.00 | 985.00 |
| Earnings per share, basic | 6.99 | 8.38 | 8.64 | 9.74 | 12.83 | 16.04 | 15.51 | 15.69 | 14.00 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.86 |
| Earnings per share, diluted | 6.99 | 8.38 | 8.64 | 9.74 | 12.83 | 16.04 | 15.51 | 15.69 | 14.00 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.86 |
Annual results, as filed
| Line | 2018-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 16,500.00 | 23,098.00 | 24,775.00 | 23,455.00 | 24,855.00 | 29,002.00 | 31,724.00 | 33,653.00 |
| Other income | 102.00 | 86.00 | 381.00 | 320.00 | 291.00 | 557.00 | 622.00 | 492.00 |
| Total income | 16,602.00 | 23,185.00 | 25,155.00 | 23,776.00 | 25,146.00 | 29,559.00 | 32,346.00 | 34,145.00 |
| Cost of materials consumed | 5,629.00 | 7,725.00 | 8,317.00 | 7,372.00 | 9,653.00 | 10,776.00 | 10,737.00 | 10,305.00 |
| Purchases of stock-in-trade | 1,606.00 | 2,112.00 | 2,315.00 | 1,952.00 | 2,050.00 | 2,773.00 | 2,887.00 | 3,478.00 |
| Changes in inventories | -483.00 | -102.00 | -730.00 | 817.00 | -410.00 | -946.00 | -598.00 | -295.00 |
| Employee benefit expense | 2,131.00 | 3,219.00 | 3,535.00 | 3,451.00 | 3,522.00 | 3,923.00 | 4,476.00 | 5,190.00 |
| Finance costs | 78.00 | 160.00 | 74.00 | 49.00 | 140.00 | 290.00 | 457.00 | 384.00 |
| Depreciation and amortisation | 558.00 | 967.00 | 1,055.00 | 1,127.00 | 1,245.00 | 1,522.00 | 1,649.00 | 1,778.00 |
| Other expenses | 3,844.00 | 5,319.00 | 6,004.00 | 5,478.00 | 6,321.00 | 6,633.00 | 7,639.00 | 8,129.00 |
| Total expenses | 13,364.00 | 19,400.00 | 20,571.00 | 20,244.00 | 22,522.00 | 24,970.00 | 27,248.00 | 28,970.00 |
| Profit before exceptional items and tax | 3,238.00 | 3,784.00 | 4,584.00 | 3,532.00 | 2,624.00 | 4,589.00 | 5,098.00 | 5,176.00 |
| Exceptional items | 0.00 | -26.00 | 2,815.00 | -128.00 | 0.00 | -192.00 | 0.00 | -65.00 |
| Profit before tax | 3,238.00 | 3,758.00 | 7,399.00 | 3,404.00 | 2,624.00 | 4,397.00 | 5,098.00 | 5,110.00 |
| Current tax | 712.00 | 957.00 | 2,325.00 | 719.00 | 1,071.00 | 1,778.00 | 1,700.00 | 1,736.00 |
| Deferred tax | 106.00 | -43.00 | -316.00 | 7.00 | -387.00 | -567.00 | -117.00 | -127.00 |
| Tax expense | 818.00 | 914.00 | 2,010.00 | 726.00 | 685.00 | 1,211.00 | 1,583.00 | 1,609.00 |
| Profit for the period | 2,423.00 | 2,830.00 | 5,334.00 | 2,647.00 | 1,928.00 | 3,169.00 | 3,484.00 | 3,503.00 |
| Profit attributable to owners | 0.00 | 2,831.00 | 5,339.00 | 2,648.00 | 1,928.00 | 3,173.00 | 3,486.00 | 3,505.00 |
| Profit attributable to non-controlling interests | -0.00 | -1.00 | -1.00 | -1.00 | 0.00 | -4.00 | -2.00 | -2.00 |
| Other comprehensive income | 150.00 | 287.00 | 5.00 | 262.00 | 736.00 | 99.00 | 304.00 | 1,965.00 |
| Total comprehensive income | 2,572.00 | 3,117.00 | 5,339.00 | 2,909.00 | 2,663.00 | 3,268.00 | 3,787.00 | 5,468.00 |
| Earnings per share, basic | 41.36 | 48.32 | 91.04 | 45.19 | 32.90 | 54.16 | 59.81 | 60.34 |
| Earnings per share, diluted | 41.36 | 48.32 | 91.04 | 45.19 | 32.90 | 54.16 | 59.81 | 60.34 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 37,167.00 | 39,890.00 | 43,924.00 | 45,072.00 | 48,094.00 | 49,785.00 | 52,546.00 | 58,502.00 |
| Non-current assets | 16,939.00 | 18,344.00 | 20,368.00 | 20,866.00 | 21,869.00 | 22,623.00 | 23,897.00 | 25,793.00 |
| Current assets | 20,143.00 | 21,546.00 | 23,552.00 | 23,772.00 | 26,226.00 | 27,162.00 | 28,649.00 | 32,709.00 |
| Property, plant and equipment | 7,809.00 | 7,995.00 | 7,870.00 | 11,546.00 | 11,428.00 | 12,189.00 | 13,281.00 | 14,330.00 |
| Capital work-in-progress | 3,666.00 | 4,496.00 | 5,798.00 | 2,739.00 | 3,497.00 | 3,266.00 | 3,039.00 | 3,009.00 |
| Goodwill | 592.00 | 596.00 | 593.00 | 595.00 | 630.00 | 618.00 | 637.00 | 800.00 |
| Other intangible assets | 2,360.00 | 2,432.00 | 2,214.00 | 2,352.00 | 2,177.00 | 1,987.00 | 1,968.00 | 2,276.00 |
| Inventories | 7,891.00 | 8,511.00 | 9,282.00 | 9,808.00 | 10,432.00 | 10,544.00 | 11,192.00 | 12,053.00 |
| Trade receivables | 3,656.00 | 4,466.00 | 4,640.00 | 4,817.00 | 5,388.00 | 5,746.00 | 5,891.00 | 7,094.00 |
| Cash and cash equivalents | 3,772.00 | 4,396.00 | 4,132.00 | 3,393.00 | 3,904.00 | 5,569.00 | 5,402.00 | 7,191.00 |
| Total equity and liabilities | 37,167.00 | 39,890.00 | 43,924.00 | 45,072.00 | 48,094.00 | 49,785.00 | 52,546.00 | 58,502.00 |
| Equity | 25,541.00 | 26,852.00 | 28,195.00 | 29,851.00 | 30,885.00 | 32,647.00 | 35,034.00 | 37,883.00 |
| Equity share capital | 59.00 | 59.00 | 59.00 | 59.00 | 58.00 | 58.00 | 58.00 | 58.00 |
| Other equity | 25,469.00 | 26,781.00 | 28,130.00 | 29,784.00 | 30,820.00 | 32,595.00 | 34,983.00 | 37,833.00 |
| Total liabilities | 11,626.00 | 13,038.00 | 15,729.00 | 15,221.00 | 17,209.00 | 17,138.00 | 17,512.00 | 20,619.00 |
| Non-current liabilities | 1,177.00 | 1,544.00 | 2,717.00 | 3,022.00 | 2,869.00 | 2,456.00 | 2,011.00 | 2,580.00 |
| Current liabilities | 10,450.00 | 11,494.00 | 13,012.00 | 12,199.00 | 14,341.00 | 14,682.00 | 15,501.00 | 18,039.00 |
| Borrowings, non-current | 290.00 | 619.00 | 1,708.00 | 2,135.00 | 1,948.00 | 1,562.00 | 1,039.00 | 803.00 |
| Borrowings, current | 3,731.00 | 4,243.00 | 4,537.00 | 4,180.00 | 6,143.00 | 6,380.00 | 6,440.00 | 6,873.00 |
| Trade payables | 3,515.00 | 3,871.00 | 4,505.00 | 4,454.00 | 4,433.00 | 4,189.00 | 4,751.00 | 5,567.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 1,892.00 | 2,387.00 | 1,500.00 | 2,435.00 | 652.00 | 3,925.00 | 2,885.00 | 5,526.00 |
| Net cash from investing activities | -3,505.00 | -3,978.00 | -3,061.00 | -4,256.00 | -708.00 | -1,875.00 | -2,223.00 | -3,458.00 |
| Net cash from financing activities | 1,218.00 | 1,814.00 | 1,293.00 | 800.00 | 545.00 | 120.00 | -943.00 | -1,269.00 |
| Purchase of property, plant and equipment | 1,117.00 | 2,404.00 | 1,496.00 | 2,780.00 | 797.00 | 1,968.00 | 1,363.00 | 2,686.00 |
| Net increase in cash | -394.00 | 223.00 | -263.00 | -1,007.00 | 511.00 | 2,178.00 | -262.00 | 1,628.00 |
| con:CFO.BEFORE_TAX | 2,283.00 | 3,121.00 | 2,275.00 | 4,201.00 | 1,406.00 | 5,656.00 | 3,667.00 | 7,358.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | -146.00 | -133.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | -129.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 391.00 | 717.00 | 642.00 | 1,767.00 | 753.00 | 1,731.00 | 782.00 | 1,832.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 688.00 | 2,014.00 | 16.00 | 4.00 | 0.00 | 23.00 | 13.00 | 788.00 |
| con:INVESTMENTS_SOLD | 36.00 | 2,457.00 | 122.00 | 179.00 | 0.00 | 111.00 | 6.00 | 6.00 |
| con:PPE_DISPOSALS | 12.00 | 11.00 | 21.00 | 60.00 | 43.00 | 3.00 | 9.00 | 46.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 197.00 | 197.00 | 0.00 | 0.00 | 12.00 | 11.00 | 0.00 | 303.00 |
| con:CF_INVESTING.JV_SOLD | 107.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 22.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 51.83 | 51.83 | 51.83 | 51.83 | 51.83 | 51.80 | 51.82 | 51.82 | 51.82 | 51.82 | 0.52 | 0.52 | 0.52 | 0.52 |
| Domestic institutions | 15.08 | 15.73 | 18.29 | 20.60 | 23.28 | 24.77 | 25.13 | 25.20 | 26.23 | 26.93 | 0.28 | 0.28 | 0.26 | 0.25 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 18.96 | 0.19 | 0.20 | 0.18 | 0.17 |
| Insurance companies | 7.20 | 7.03 | 6.67 | 5.53 | 5.03 | 5.19 | 4.66 | 5.12 | 5.44 | 5.49 | 0.06 | 0.06 | 0.05 | 0.05 |
| Foreign institutions | 23.03 | 24.13 | 22.45 | 20.72 | 18.02 | 16.73 | 16.59 | 16.29 | 15.33 | 14.37 | 0.14 | 0.14 | 0.15 | 0.16 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | — | — | — | — |
| Public | 48.17 | 48.17 | 48.17 | 48.17 | 48.17 | 48.20 | 48.18 | 48.18 | 48.18 | 48.18 | 0.48 | 0.48 | 0.48 | 0.48 |
| Non-institutional | 10.05 | 8.31 | 7.42 | 6.85 | 6.87 | 6.70 | 6.46 | 6.69 | 6.61 | 6.87 | 0.06 | 0.07 | 0.07 | 0.07 |
| Shares outstanding | 585938609 | 585938609 | 585938609 | 585938609 | 585938609 | 585938609 | 580801623 | 580801623 | 580801623 | 580801623 | 580801623 | 580801623 | 580801623 | 575377895 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| APL HEALTH CARE LIMITED | subsidiary | Any other transaction, Interest received, Investment | 22,823,750,000.00 | 12 |
| AUROBINDO PHARMA USA., INC | subsidiary | Sale of goods or services | 20,554,330,000.00 | 1 |
| Aurobindo Pharma USA Inc. | subsidiary | Any other transaction, Sale of fixed assets, Sale of | 18,567,350,000.00 | 7 |
| APITORIA PHARMA PRIVATE LIMITED | subsidiary | Any other transaction, Investment, Loan, Purchase of | 16,313,700,000.00 | 10 |
| LYFIUS PHARMA PRIVATE LIMITED | subsidiary | Any other transaction, Interest received, Investment | 12,631,240,000.00 | 9 |
| Eugia US LLC ( formerly known as Auro Medics Pharma LLC), | subsidiary | Any other transaction, Sale of goods or services | 7,078,300,000.00 | 6 |
| APL Swift Services (Malta) Ltd. | subsidiary | Purchase of goods or services, Sale of goods or serv | 5,976,550,000.00 | 2 |
| CURATEQ BIOLOGICS PRIVATE LIMITED | subsidiary | Any other transaction, Interest received, Investment | 3,972,070,000.00 | 7 |
| Puren Pharma GmbH & Co., KG | subsidiary | Any other transaction, Dividend received, Interest r | 3,618,370,000.00 | 22 |
| EUGIA PHARMA SPECIALITIES LIMITED | subsidiary | Any other transaction, Interest received, Loan, Purc | 3,003,320,000.00 | 8 |
| Aurobindo Pharma B.V. | subsidiary | Any other transaction, Dividend received, Interest r | 2,888,840,000.00 | 33 |
| Generis Farmaceutica S.A. | subsidiary | Any other transaction, Dividend received, Sale of go | 2,573,560,000.00 | 15 |
| ARROW GENERIQUES | subsidiary | Purchase of goods or services, Sale of goods or serv | 1,980,380,000.00 | 4 |
| Pravesha Industries Private Limited, India | Enterprises over which key managem | Purchase of fixed assets, Purchase of goods or servi | 1,890,330,000.00 | 3 |
| Aurovitas Spain SA | subsidiary | Any other transaction, Sale of goods or services | 1,886,680,000.00 | 13 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-05-27 | Q4FY26 | Read the call | |
| 2026-02-16 | Q3FY25 | Read the call | |
| 2025-11-11 | Q2FY26 | Read the call | |
| 2025-08-08 | Q1FY26 | Read the call | |
| 2025-06-02 | Q4FY25 | Read the call | |
| 2025-02-13 | FYFY25 | Read the call | |
| 2024-11-18 | Q2FY25 | Read the call | |
| 2024-08-16 | Q1FY24 | Read the call | |
| 2024-05-31 | Q4FY24 | Read the call | |
| 2024-02-16 | Q3FY23 | Read the call | |
| 2023-11-15 | Q2FY24 | Read the call | |
| 2023-08-18 | Q1FY24 | Read the call | |
| 2023-06-01 | Q4FY23 | Read the call | |
| 2023-02-17 | Q3FY23 | Read the call | |
| 2022-11-18 | Q2FY23 | Read the call | |
| 2022-08-19 | Q1FY23 | Read the call | |
| 2022-06-06 | Q4FY22 | Read the call | |
| 2022-02-17 | Q3FY22 | Read the call | |
| 2021-11-19 | Q2FY22 | Read the call | |
| 2021-08-25 | Q1FY22 | ARVIND, AUROBINDO PHARMA USA, INVESTOR, OFFICER, AUROBINDO PHARMA LIMITED | Read the call |
| 2021-06-11 | Q4FY21 | & CORPORATE COMMUNICATIONS, AUROBINDO, CHAIRMAN, AUROBINDO PHARMA USA, HEAD, FORMULATIONS, | Read the call |
| 2021-02-25 | Q3FY21 | AUROBINDO PHARMA LIMITED, PHARMA LIMITED | Read the call |
| 2020-11-27 | Q2FY21 | CHAIRMAN, AUROBINDO PHARMA USA, PHARMA LIMITED | Read the call |
| 2020-08-25 | Q1FY21 | AUROBINDO PHARMA LIMITED, PHARMA LIMITED | Read the call |
| 2020-06-18 | Q4FY20 | AUROBINDO PHARMA LIMITED, AUROBINDO PHARMA USA, – AUROBINDO PHARMA USA | Read the call |
| 2020-02-24 | Q3FY20 | PHARMA LIMITED | Read the call |
| 2019-11-28 | Q2FY20 | CHAIRMAN, AUROBINDO PHARMA USA | Read the call |
| 2019-08-19 | Q1FY20 | AUROBINDO PHARMA LIMITED | Read the call |
| 2019-06-14 | Q4FY19 | DIRECTOR, AUROBINDO PHARMA LIMITED, MR. KRISHNA, PHARMA LIMITED | Read the call |
| 2019-02-22 | Q3FY19 | CHAIRMAN, AUROBINDO PHARMA USA, PHARMA LIMITED | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q4FY19 | Q4FY20 | Q4FY21 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | Net organic CAPEX for the quarter is around $63 million. | Net organic capex for the quarter is around $37 million. | CAPEX for the quarter is around US$88 million. | Net organic CAPEX for the quarter is around $65 million. | Net capex for the quarter is around USD 105 million, of which capex for existing businesses 62 million, including USD 14 million for ANDA purchases. | The net capex for the quarter is US$70mn which mainly includes approximately US$33mn towards the Pen- G projects. | Net capital for the quarter is US$ 90 million and that for the year is around US$ 322 million, which includes capacity enhancement projects, new plant… | For the year, R&D expenditure stood at ₹1,590 crores, which is 5% of revenue. • Net CapEx for the quarter is $82 million and for the year around $341 … |
| Capital allocation | In the month of March, we have successfully completed the acquisition of seven branded Oncology injectable products from Spectrum Pharmaceuticals. | Got it Sir, thank you and the last question is on branded oncology so we have now seen one year of this acquisition almost so just wanted to get a sen… | We are not looking at any large ticket acquisition at this juncture. | Sir just one more, Sir you starting to build up a nice cash file now but given the challenges in developed markets does it make sense to keep acquirin… | Couple of quarters back so you had spoken about the possibility of some kind of buyback or higher dividend, so just wanted to check are we still think… | At present we are manufacturing around 47 billion units of formulation. • Expanding growth market with a recent foray into the Indonesian market with … | The last buyback was closed on August 31st 2024. | We are not going for any big bang acquisition, at least I hope we don’t. |
| Costs | — | — | On raw material side, we have seen some companies talking about increase in API prices for particular products. | The average raw material cost increased by about 9% during the quarter and freight costs are more than 10% on year and quarter. | The average raw material cost remained flat during the quarter, and the freight cost also reduced during the quarter. | The profitability of the company has improved significantly backed by softening of raw material prices, favourable product and business mix and improv… | The profitability of the company as well improved significantly, backed by softening of raw material prices, favourable product and business mix, and … | We are not buying it from the imported material and because of that our raw material cost will come down and the other expenses goes up. |
| Debt and cash | May 29, 2019 The net debt has increased by $166 million QoQ to $724 million mainly due to acquisition of Apotex’s businesses and branded Oncology prod… | The net debt has decreased by $87 million quarter-on-quarter to $359 million at the end of March 2020, on a full year basis net debt had reduced by $3… | So, anything that you would want to call out here in terms of maybe some of the non-operating working capital items or any other reasons for lower ope… | The business generated a free cash flow of $38 million during this quarter. | The business generated a free cash flow of USD 61 million during the quarter, as result of strong cash flows generated during the quarter. | The average USD INR exchange rate is 83.04 against 83.24 in Q3 FY24. The business has a net cash flow of US$12mn during this quarter before the Pen-G … | Our cash flows have improved significantly on the backdrop of improved working capital position, leading to a net cash surplus of US$ 42 million versu… | So, we have to ensure that the inventory buildup is not happening, working capital is not locked in. |
| Demand | But if we are talking about substantial jump, then it requires new products, and that is not what is in our pipeline. | Then there were also opportunities that have been created when other companies probably had some supply issues, so we saw certain surge in the demand. | Apart from that, we have a large investment which has been made on the differentiated portfolio, which includes biosimilars as Mr. Reddy was explainin… | What is also important to note in terms of our biosimilars for some of you following the business closely is that we are stronger in our pipeline with… | Or, with the R&D pipeline, we can manage? | With Aurobindo Pharma Limited May 2024 continued investment in R&D, we continue to develop strong growth pipeline. | And the second question I have on the US, is it possible to give some colour on the pipeline for the US market? | Coming to the U.S. business, we continue to see multiple growth levers through the expansion of base business, new product launches, i.e. topical oint… |
| Guidance | How many launches are we expecting in Injectables this year? | In fact, next year we expect R&D cost to be around 5.5% as clinicals for the biosimilars as well as depots will start. | We expect the SEC approval to happen as we progress and once that approval happens from the DCGI, we would be starting the trial in India. | Sir, My question is what is your guidance for the future, does it remain intact, I mean you know or is there any change or what is basically your guid… | We expect to continue this. - We expect to see some good cash generation from FY25 onwards after capitalising all the assets which have been enumerate… | For the year FY24, we achieved 29,002 crore of sales exceeding our internal target of Rs.28,500 crores plus and achieved an EBITDA margin of 20.1% aga… | This plant is expected to contribute revenues in FY26. We expect our US-based OSD plant at Dayton to be commercialized during FY26. Our other plant in… | We expect the business momentum in the region to remain strong going forward. |
| Margin | The EBITDA before FOREX and other income increased by 4% YoY to | EBITDA margin for the year was at 21.1%, an improvement of 90 basis points over corresponding previous period. | The EBITDA before FOREX and other income increased by 9% year-on-year to Rs.4,997 crores. | The EBITDA before FOREX and other income declined by 23.6% year on year and declined by 4% quarter-on- quarter to ₹974.74 crores. | The EBITDA before forex and other income grew by 2.8% year on year, and by 5% quarter on quarter to Rs. | We had the highest ever sales and EBITDA for the quarter and the year. | I am delighted to start the call by sharing with you that it has been an excellent quarter and the financial year for the company, marked by continued… | I am pleased to begin the call by sharing that the company has delivered an excellent quarter and a strong financial year, underpinned by sustained gr… |
| People | — | Our manufacturing units continued to function at healthy capacity utilization levels. | You are exploring opportunities for further utilization of the capacities for any other contract manufacturing services or any other vaccine manufactu… | Can you talk about the capacity utilization for your oral solid manufacturing units at a consolidated level? | — | The growth in the API business is mainly driven by higher volumes on account of improved asset utilization and debottlenecking. | The growth in the API business is mainly driven by higher volumes, on account of improved asset utilization with higher capacities. | You know, we are going to reach that kind of level now with an 80% cap utilization. |
| Pricing | For Sandoz business, we had made some estimates post factoring certain variables such as the competition and the pricing. | We are in line with the overall market share percentage that we have been maintaining so this is one reason why there is a fair amount of drop, this i… | — | This year has been very challenging due to various factors namely COVID, steep crude price increases, global inflation, and second of geopolitical iss… | In terms of pricing, right now it remains high. | It has been a good year performance across the businesses mainly driven by volume gains, new product launches, our expansion in to new growth markets … | Aurobindo Pharma Limited 27 May 2025 During the year and quarter, we saw good performance across all businesses, mainly driven by volume gains, new pr… | During both the quarter and financial year, we witnessed good performance across our businesses, primarily driven by stable volumes, new product launc… |
| Revenue growth | The growth was on the back of healthy growth across business segments and the geographies. | In terms of the “Business Breakdown”, Formulation business in FY20 witnessed a growth of 24% year-on-year to Rs 20,012 Crores and contributed around 8… | In terms of the Business Breakdown, Formulations business in FY ‘21 witnessed a growth of 9% year-on-year to Rs.20,592 crores. | API business contributed around 16% and clocked the revenue of ₹913 crore for the quarter registering a growth of 15% on a YOY basis led by improved d… | In terms of the business breakdown, Formulation business in Q4 FY23 witnessed a growth of 11.4% year on year to 5,455 crores and contributed around 84… | In terms of the business breakdown, formulation business excluding Puerto Rico in Q4 witnessed a growth of 21% year on year to Rs. | Formulation business witnessed a growth of 12% year-on-year to Rs. | Despite insignificant Revlimid product sales compared to Q4 FY25, EBITDA before Forex remained flat year-on-year growth and grew by 2% on quarter to ₹… |